French John K, Feldman Henry A, Assmann Susan F, Sanborn Timothy, Palmeri Sebastian T, Miller David, Boland Jean, Buller Christopher E, Steingart Richard, Sleeper Lynn A, Hochman Judith S
Department of Cardiology, Green Lane Hospital, Auckland, New Zealand.
Am Heart J. 2003 Nov;146(5):804-10. doi: 10.1016/S0002-8703(03)00392-2.
The enhancement of diastolic coronary blood flow by the combination of thrombolytic therapy (TT) and intra-aortic balloon counterpulsation (IABP) in experimental studies provides a rationale for their combined use in acute myocardial infarction (MI) complicated by cardiogenic shock. We examined the relation between TT (with and without IABP) and 12-month survival in the SHould We Emergently Revascularize Occluded Coronaries for Cardiogenic ShocK (SHOCK) Trial.
Among 302 patients with myocardial infarction and cardiogenic shock who were randomized in the SHOCK Trial, 16 had absolute contraindications to TT. Among 150 patients randomly assigned to initial medical stabilization (IMS), 63% received TT, as recommended per protocol, compared with 49% of 152 patients randomly assigned to emergency revascularization, in whom TT was not recommended if immediate angiography was available. IABP deployment, which was protocol-recommended, was used in 86% of patients. The rate of severe bleeding was similar in patients receiving TT and in those not receiving TT (31% vs 26%, P =.37). Among patients randomly assigned to IMS, TT was associated with improved 12-month survival (unadjusted mortality hazard ratio, 0.59; P =.01; mortality hazard ratio adjusted for age and prior MI, 0.62; P =.02). TT was not associated with improved 12-month survival among patients randomly assigned to emergency revascularization (unadjusted mortality hazard ratio, 0.93; P =.76; mortality hazard ratio adjusted for age and prior MI, 1.06, P =.81). The test for interaction of TT and randomization group P value was.16, and there was insufficient statistical power to demonstrate a differential effect of TT on 12-month survival by treatment group assignment.
Among patients randomly assigned to IMS in the SHOCK Trial, TT was associated with improved 12-month survival and did not significantly increase the risk of severe bleeding.
实验研究表明,溶栓治疗(TT)与主动脉内球囊反搏(IABP)联合应用可增强舒张期冠状动脉血流,这为二者在合并心源性休克的急性心肌梗死(MI)中联合使用提供了理论依据。我们在“心源性休克时是否应紧急对闭塞冠状动脉进行血运重建”(SHOCK)试验中研究了TT(联合或不联合IABP)与12个月生存率之间的关系。
在SHOCK试验中随机分组的302例心肌梗死合并心源性休克患者中,16例有TT的绝对禁忌证。在随机分配至初始药物稳定治疗(IMS)的150例患者中,按照方案推荐,63%接受了TT,而在随机分配至紧急血运重建的152例患者中,这一比例为49%,如果可立即进行血管造影,则不推荐在这些患者中使用TT。按照方案推荐使用IABP的患者比例为86%。接受TT的患者与未接受TT的患者严重出血发生率相似(31%对26%,P = 0.37)。在随机分配至IMS的患者中,TT与12个月生存率提高相关(未调整的死亡风险比,0.59;P = 0.01;经年龄和既往心肌梗死调整后的死亡风险比,0.62;P = 0.02)。在随机分配至紧急血运重建的患者中,TT与12个月生存率提高无关(未调整的死亡风险比,0.93;P = 0.76;经年龄和既往心肌梗死调整后的死亡风险比,1.06,P = 0.81)。TT与随机分组的交互作用检验P值为0.16,且统计效能不足,无法证明TT对12个月生存率的影响因治疗组分配而异。
在SHOCK试验中随机分配至IMS的患者中,TT与12个月生存率提高相关,且未显著增加严重出血风险。